NYSE:NSPR InspireMD (NSPR) Stock Price, News & Analysis → Did You Get Your Free Bitcoin Yet? (From Crypto Swap Profits) (Ad) Free NSPR Stock Alerts $1.99 +0.07 (+3.65%) (As of 04/26/2024 ET) Add Compare Share Share Today's Range$1.94▼$2.0250-Day Range$1.85▼$2.7752-Week Range$1.03▼$3.85Volume10,249 shsAverage Volume33,639 shsMarket Capitalization$46.57 millionP/E RatioN/ADividend YieldN/APrice Target$4.85 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsSocial Media Get InspireMD alerts: Email Address InspireMD MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside143.7% Upside$4.85 Price TargetShort InterestN/ADividend StrengthN/ASustainabilityN/ANews Sentiment0.30Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.61) to ($0.50) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.07 out of 5 starsMedical Sector487th out of 908 stocksSurgical & Medical Instruments Industry56th out of 97 stocks 3.5 Analyst's Opinion Consensus RatingInspireMD has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageInspireMD has received no research coverage in the past 90 days. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for NSPR. Previous Next 0.0 Dividend Strength Dividend YieldInspireMD does not currently pay a dividend.Dividend GrowthInspireMD does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for NSPR. Previous Next 1.8 News and Social Media Coverage News SentimentInspireMD has a news sentiment score of 0.30. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for InspireMD this week, compared to 0 articles on an average week. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, InspireMD insiders have not sold or bought any company stock.Percentage Held by Insiders21.62% of the stock of InspireMD is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions44.78% of the stock of InspireMD is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for InspireMD are expected to grow in the coming year, from ($0.61) to ($0.50) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of InspireMD is -1.85, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of InspireMD is -1.85, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioInspireMD has a P/B Ratio of 1.09. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Banyan Hill PublishingThe Best AI Stock to Own in the World Today is Trading for Just $25“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.See how you can invest alongside him About InspireMD Stock (NYSE:NSPR)InspireMD, Inc., a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions. InspireMD, Inc. has a strategic agreement with Jacobs Institute to execute an early feasibility study of CGuard Prime for the treatment of acute stroke patients with tandem lesions. The company sells its products through local distribution partners. InspireMD, Inc. was founded in 2005 and is headquartered in Tel Aviv-Yafo, Israel.Read More NSPR Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart NSPR Stock News HeadlinesApril 26, 2024 | ca.finance.yahoo.comInspireMD, Inc. (NSPR)April 24, 2024 | americanbankingnews.comInspireMD (NYSE:NSPR) Now Covered by Analysts at StockNews.comApril 26, 2024 | Colonial Metals (Ad)Conflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareThe latest flare-up between Israel and Palestinian militants has sent gold prices surging. Why? Because savvy investors know the endgame of the elites at play… Geopolitical crises breed uncertainty — and gold thrives on uncertainty. April 3, 2024 | finance.yahoo.comInspireMD to Present at the 23rd Annual Needham Virtual Healthcare ConferenceApril 3, 2024 | globenewswire.comInspireMD to Present at the 23rd Annual Needham Virtual Healthcare ConferenceMarch 31, 2024 | msn.comPope Francis appeals for Gaza cease-fire and Russia-Ukraine prisoner swap in Easter Sunday prayersMarch 26, 2024 | globenewswire.comInspireMD Announces Abstract of One-Year Follow-Up Results from the C-GUARDIANS U.S. Investigational Device Exemption (IDE) Clinical Trial Accepted for Presentation at LINC 2024March 6, 2024 | finanznachrichten.deInspireMD, Inc.: InspireMD Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business UpdateApril 26, 2024 | Colonial Metals (Ad)Conflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareThe latest flare-up between Israel and Palestinian militants has sent gold prices surging. Why? Because savvy investors know the endgame of the elites at play… Geopolitical crises breed uncertainty — and gold thrives on uncertainty. March 6, 2024 | investorplace.comNSPR Stock Earnings: InspireMD Beats EPS, Beats Revenue for Q4 2023March 6, 2024 | globenewswire.comInspireMD Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business UpdateMarch 5, 2024 | benzinga.comPreview: InspireMD's EarningsFebruary 28, 2024 | globenewswire.comInspireMD to Report Fourth Quarter and Full-Year 2023 Financial Results and Provide Corporate Business Update on Wednesday, March 6thFebruary 21, 2024 | ca.finance.yahoo.comNSPR Mar 2024 7.500 callFebruary 1, 2024 | msn.comInspireMD Announces CE Mark Recertification Under MDRFebruary 1, 2024 | msn.comInspireMD Secures CE Mark Recertification Under New EU StandardsJanuary 23, 2024 | finance.yahoo.comWe're Hopeful That InspireMD (NASDAQ:NSPR) Will Use Its Cash WiselyNovember 27, 2023 | msn.comInspireMD (NSPR) Price Target Increased by 11.49% to 4.95November 23, 2023 | msn.comDown -24.61% in 4 Weeks, Here's Why InspireMD, Inc. (NSPR) Looks Ripe for a TurnaroundNovember 6, 2023 | markets.businessinsider.comInspireMD earnings: here's what Wall Street expectsNovember 6, 2023 | msn.comInspireMD GAAP EPS of -$0.15 misses by $0.01, revenue of $1.56M beats by $0.06MNovember 6, 2023 | finance.yahoo.comInspireMD Reports Third Quarter 2023 Financial Results and Provides Business UpdateNovember 3, 2023 | msn.comInspireMD Q3 2023 Earnings PreviewNovember 1, 2023 | markets.businessinsider.comInspireMD Presents Positive 30-Day Follow-Up Results from the C-GUARDIANS U.S. Investigational Device Exemption (IDE) Clinical Trial at VIVA23September 25, 2023 | markets.businessinsider.comPiper Sandler Remains a Buy on InspireMD (NSPR)September 22, 2023 | finance.yahoo.comInspireMD's CGuard(TM) Carotid Embolic Prevention System Featured in Live Case at Cracow Vascular Summit 2017 in PolandAugust 31, 2023 | msn.comInspireMD (NSPR) Price Target Increased by 5.45% to 4.44See More Headlines Receive NSPR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for InspireMD and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/06/2024Today4/26/2024Next Earnings (Estimated)5/20/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Surgical & medical instruments Sub-IndustryN/A Current SymbolNYSE:NSPR CUSIPN/A CIK1433607 Webwww.inspiremd.com Phone9728887766804FaxN/AEmployees65Year FoundedN/APrice Target and Rating Average Stock Price Target$4.85 High Stock Price Target$5.20 Low Stock Price Target$4.50 Potential Upside/Downside+149.4%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($1.08) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-19,920,000.00 Net Margins-320.97% Pretax Margin-319.92% Return on Equity-55.71% Return on Assets-46.53% Debt Debt-to-Equity RatioN/A Current Ratio7.34 Quick Ratio6.99 Sales & Book Value Annual Sales$6.20 million Price / Sales7.34 Cash FlowN/A Price / Cash FlowN/A Book Value$1.83 per share Price / Book1.06Miscellaneous Outstanding Shares23,400,000Free Float18,342,000Market Cap$45.51 million OptionableOptionable Beta0.83 These 7 Stocks Will Be Magnificent in 2024With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.Get This Free Report Key ExecutivesMr. Marvin L. Slosman (Age 60)President, CEO & Director Comp: $696.81kMr. Craig Shore (Age 63)CFO, Chief Administrative Officer, Secretary & Treasurer Comp: $625.24kMr. Andrea Tommasoli (Age 52)Chief Operating Officer Comp: $359.27kMr. Amir KohenVice President of Finance & Human ResourcesMr. Shane Thomas Gleason (Age 49)Chief Commercial Officer Dr. Patrick A. Verta DVM (Age 66)M.D., MS Stat, Executive Vice President of Clinical & Medical Affairs Mr. Pete LigottiExecutive VP & GM of North AmericaDr. Sol J. Barer Ph.D. (Age 77)Special Advisor to the Board Comp: $13.92kMore ExecutivesKey CompetitorsDaxorNASDAQ:DXRApyx MedicalNASDAQ:APYXCytosorbentsNASDAQ:CTSOBeyond AirNASDAQ:XAIRDarioHealthNASDAQ:DRIOView All CompetitorsInsiders & InstitutionsMesirow Financial Investment Management Inc.Bought 30,000 shares on 4/26/2024Ownership: 0.128%Rosalind Advisors Inc.Sold 239,132 shares on 4/25/2024Ownership: 2.932%McKinley Carter Wealth Services Inc.Bought 10,000 shares on 2/7/2024Ownership: 0.046%Gary S RoubinBought 50,000 shares on 11/30/2023Total: $126,500.00 ($2.53/share)Paul StukaBought 175,000 shares on 5/12/2023Total: $285,250.00 ($1.63/share)View All Insider TransactionsView All Institutional Transactions NSPR Stock Analysis - Frequently Asked Questions Should I buy or sell InspireMD stock right now? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for InspireMD in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" NSPR shares. View NSPR analyst ratings or view top-rated stocks. What is InspireMD's stock price target for 2024? 1 equities research analysts have issued 1 year price targets for InspireMD's stock. Their NSPR share price targets range from $4.50 to $5.20. On average, they expect the company's stock price to reach $4.85 in the next year. This suggests a possible upside of 143.7% from the stock's current price. View analysts price targets for NSPR or view top-rated stocks among Wall Street analysts. How have NSPR shares performed in 2024? InspireMD's stock was trading at $2.81 at the beginning of the year. Since then, NSPR shares have decreased by 29.2% and is now trading at $1.99. View the best growth stocks for 2024 here. When is InspireMD's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024. View our NSPR earnings forecast. How were InspireMD's earnings last quarter? InspireMD, Inc. (NYSE:NSPR) announced its quarterly earnings results on Wednesday, March, 6th. The company reported ($0.16) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.20) by $0.04. The firm earned $1.76 million during the quarter, compared to analyst estimates of $1.65 million. InspireMD had a negative net margin of 320.97% and a negative trailing twelve-month return on equity of 55.71%. During the same quarter last year, the business earned ($0.60) earnings per share. What other stocks do shareholders of InspireMD own? Based on aggregate information from My MarketBeat watchlists, some companies that other InspireMD investors own include Akorn (AKRXQ), Akers Biosciences (AKER), Akebia Therapeutics (AKBA), Adamis Pharmaceuticals (ADMP), ADMA Biologics (ADMA), Acasti Pharma (ACST), AcelRx Pharmaceuticals (ACRX), Acorda Therapeutics (ACOR), Aurora Cannabis (ACB) and Ambev (ABEV). Who are InspireMD's major shareholders? InspireMD's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Rosalind Advisors Inc. (2.93%) and Mesirow Financial Investment Management Inc. (0.13%). Insiders that own company stock include Gary S Roubin and Paul Stuka. View institutional ownership trends. How do I buy shares of InspireMD? Shares of NSPR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NYSE:NSPR) was last updated on 4/26/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersHe Is Giving Away BitcoinCrypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithMan Who Predicted 2008: “This Will be Worse.”AltimetryFed launches fourth dollar overhaulStansberry ResearchBiden out June 13; Kamala won’t replace him?Paradigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding InspireMD, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
